Surgery delivered three times the symptom relief of antibiotics
For the roughly one in eleven people on Earth who live with the persistent fog of chronic sinusitis — the blocked passages, the facial ache, the vanished sense of smell — medicine has long offered a familiar first answer: antibiotics. A landmark trial published in The Lancet now quietly unsettles that assumption, finding that surgical intervention produced symptom relief three times greater than medication, inviting clinicians to reconsider not just a treatment protocol, but the deeper question of when the scalpel serves the patient better than the pill.
- Millions of chronic sinusitis sufferers endure months or years of nasal obstruction and facial pain under a treatment model that a major new trial suggests may be fundamentally inadequate.
- A 500-patient study found surgery delivered a 30-point symptom improvement versus just 10 points for antibiotics or placebo — a gap too wide for the medical community to comfortably ignore.
- The trial is the first large-scale head-to-head comparison of surgery versus antibiotics in this population, directly challenging the entrenched clinical habit of exhausting medication options before considering an operation.
- A critical complication clouds the findings: 80% of participants had nasal polyps — a prevalence researchers suspect is tied to post-COVID inflammation — raising questions about whether the surgical advantage holds for patients without polyps.
- The field now faces a call for further research to determine whether these results extend across different sinusitis profiles, leaving clinicians in a transitional moment between old assumptions and emerging evidence.
For the roughly one in eleven people on the planet living with chronic sinusitis, the experience is relentless — clogged nasal passages, persistent facial pain, and a sense of smell that fades or disappears entirely. Medicine's standard response has long been antibiotics, particularly claritromycin prescribed over three-month courses, with surgery reserved as a last resort.
A new study published in The Lancet challenges that hierarchy directly. Researchers divided more than 500 adults with chronic sinusitis into three groups: one took claritromycin, one received a placebo, and one underwent nasal surgery to widen the sinuses and remove benign polyps. All participants continued baseline care with anti-inflammatory sprays and saline rinses.
Six months later, the divergence was striking. The antibiotic and placebo groups each reported roughly 10 points of improvement on a 110-point severity scale — real, but modest. The surgical group averaged 30 points of improvement. For patients whose sinusitis had resisted conventional treatment, reshaping the nasal passages outperformed medication by a factor of three.
The significance lies partly in what was missing before: no large-scale trial had ever made this direct comparison. Doctors had operated on intuition and smaller studies, defaulting to antibiotics because suppressing infection chemically seemed logical. This trial reorders that logic — at least for certain patients.
The caveat is substantial. Around 80 percent of study participants had nasal polyps, a rate researchers suspect may be elevated due to COVID-19-related inflammation. That raises the possibility that the surgical benefit is specific to polyp-bearing patients and may not translate to those with different underlying disease patterns. Further research will be needed before the findings can be applied universally — but for now, the assumption that surgery should always come last has been meaningfully questioned.
For millions of people worldwide, chronic sinusitis is a grinding, persistent problem. The nasal passages stay clogged. The face aches. The sense of smell fades or vanishes entirely. These symptoms drag on for months, sometimes years, affecting roughly one in eleven people on the planet. When the mucus-producing cavities in the sinuses become inflamed, the body struggles to clear them, and conventional medicine has long reached for the same tool: antibiotics, particularly a drug called claritromycin, prescribed in three-month courses.
But a new study published in The Lancet suggests that approach may be missing something fundamental. Researchers recruited more than 500 adults with chronic sinusitis and divided them into three groups. One took claritromycin for three months. Another received placebo pills. The third underwent nasal surgery to widen the sinuses and remove benign polyps. All participants continued using anti-inflammatory nasal sprays and saline rinses—the standard baseline care everyone receives.
Six months later, the results diverged sharply. Patients on claritromycin or placebo reported symptom improvement of about 10 points on a 110-point severity scale. That's real relief, but modest. The surgical group, by contrast, showed improvement averaging 30 points—three times as much. The difference was not marginal. It suggested that for people whose sinusitis had resisted conventional treatment, cutting and reshaping the nasal passages delivered substantially better outcomes than medication alone.
The finding matters because until now, no large-scale trial had directly compared surgery to antibiotics in this population. Doctors had relied on clinical experience and smaller studies. The antibiotic approach made intuitive sense: if infection or inflammation was the problem, suppress it chemically. Surgery was reserved for last resorts. This trial reorders that logic, at least for certain patients.
There is, however, a significant caveat. About 80 percent of the study participants had nasal polyps—benign growths that obstruct the passages and worsen symptoms. Researchers suspect the unusually high prevalence may be linked to COVID-19, since coronavirus infection can trigger the kind of inflammation that spawns these polyps. That means the study's results may not apply cleanly to people with chronic sinusitis who lack polyps, who suffer from different underlying inflammation patterns. The surgical benefit observed here might be specific to the polyp-bearing subset.
The implication is clear but incomplete. Surgery appears to work better than antibiotics for chronic sinusitis, at least in this cohort. But the medical community will need additional research to understand whether those results hold for patients with different disease profiles. For now, the study challenges a long-standing assumption: that medication should always come first, and surgery only when everything else fails. For some people, the evidence suggests, the order may need reversing.
Notable Quotes
Surgery may provide substantially greater benefit than antibiotic treatment for chronic sinusitis— The Lancet study findings
The Hearth Conversation Another angle on the story
Why did it take so long for someone to actually test surgery against antibiotics directly?
Because surgery is invasive and carries risk. Doctors naturally prefer to try medication first. But that preference was never really tested head-to-head in a rigorous way. It was just how the field evolved.
So the 30-point improvement versus 10-point—that's not just statistically significant, it's clinically meaningful?
Yes. A patient with a score of 55 out of 110 is genuinely suffering. Dropping to 25 changes daily life. You can breathe. You can smell. The difference between 10 and 30 points is the difference between "I feel a little better" and "I feel substantially better."
But the polyp thing troubles me. If 80 percent of the study had polyps, aren't we really testing surgery for polyp disease, not sinusitis broadly?
Exactly. That's the honest limitation. We don't know if surgery helps the 20 percent without polyps the same way. The inflammation mechanism might be entirely different. You need another trial.
Could the COVID connection be temporary? Will those polyps go away on their own?
That's unknown. The study doesn't tell us. But it raises a real question: are we seeing a pandemic-specific phenomenon, or a durable finding about how to treat sinusitis?
What happens to the people who got placebo? Do they eventually get surgery?
The study doesn't say. But in real practice, yes—if you're in a trial and you're still suffering after six months, you'd likely pursue surgery next. The placebo group proved that sprays and rinses alone aren't enough for severe cases.
So for someone suffering right now, what does this mean?
It means if you've tried medication for months and you're still miserable, surgery is worth a serious conversation with your doctor. It's not a last resort anymore—it's a legitimate option with real evidence behind it.